Abstract
Inflammatory diseases are often characterised by excessive neutrophil infiltration from the blood stream to the site of inflammation, which damages healthy tissue and prevents resolution of inflammation. Development of anti-inflammatory drugs is hindered by lack of in vitro and in vivo models which accurately represent the disease microenvironment. In this study, we used the OrganoPlate to develop a humanized 3D in vitro inflammation-on-a-chip model to recapitulate neutrophil transmigration across the endothelium and subsequent migration through the extracellular matrix (ECM). Human umbilical vein endothelial cells formed confluent vessels against collagen I and geltrex mix, a mix of basement membrane extract and collagen I. TNF-α-stimulation of vessels upregulated inflammatory cytokine expression and promoted neutrophil transmigration. Intriguingly, major differences were found depending on the composition of the ECM. Neutrophils transmigrated in higher number and further in geltrex mix than collagen I, and did not require an N-formyl-methionyl-leucyl-phenylalanine (fMLP) gradient for transmigration. Inhibition of neutrophil proteases inhibited neutrophil transmigration on geltrex mix, but not collagen I. These findings highlight the important role of the ECM in determining cell phenotype and response to inhibitors. Future work could adapt the ECM composition for individual diseases, producing accurate models for drug development.
Subject terms: Lab-on-a-chip, Innate immunity, Inflammation, Acute inflammation
Introduction
Inflammatory responses are required to successfully combat invasion by pathogens. However, excessive or unresolved inflammation can damage healthy tissue and result in chronic inflammatory conditions such as rheumatoid arthritis, ulcerative colitis, cardiomyopathies, cardiovascular disease, and asthma.
During an inflammatory response, neutrophils move from the blood to the site of inflammation by transmigrating across the endothelial barrier and through the basement membrane (BM) of the surrounding extracellular matrix (ECM). This multi-step process is enabled by inflammatory receptors and molecules expressed by the endothelial cells which capture the neutrophils and support their extravasation, alongside gradients of chemokines that guide the neutrophils through the ECM. The neutrophils respond by upregulating integrins that allow attachment to the endothelium and subsequently aid their movement through the BM1. These events must be tightly regulated to prevent excessive inflammation and tissue damage. Conversely, neutrophil transmigration is a potential drug target for treatment of chronic inflammatory conditions. However, crucial to developing novel therapies is a clear understanding of how neutrophil transmigration is regulated.
Neutrophil transmigration in vivo occurs in a 3D environment, and therefore typical 2D in vitro techniques cannot accurately recapitulate the process2,3. Static assays such as transwell migration in Boyden chambers4 are hindered by effects of gravity, lack of physiological flow, and difficulty in visualizing and analysing the neutrophils at each stage of transmigration. Equally, studying neutrophils using in vivo animal models has important ethical implications and can inaccurately model human physiology5. For example, in humans neutrophils comprise 50–70% of circulating leukocytes, compared to just 10–25% in mice6. Additionally, some cytokines found to play an important role in human inflammation such as IL-87, are not expressed by mice. This lack of translation from current in vitro and in vivo models into humans has led to challenges in drug discovery8.
Organ-on-a-chip is a new and fast-growing field that has the potential to cross the translation gap and provide humanized models for use in both basic biology research and drug discovery. These computer chip-sized devices provide cells with a more physiological 3D environment that supports cell differentiation, enabling organ-like functions. The chips commonly consist of channels coated with ECM proteins and lined with one or more cell types. Additional physical factors such as shear flow, air–liquid interfaces, and cyclical deformation of the chips can also be incorporated9,10. With developments in stem cell biology, there is potential to derive cells from induced pluripotent stem cells of patient samples, increasing the feasibility of personalised medicine11. To reach this stage, models of different organs and biological processes and/or diseases need to be developed. Although the field is still relatively new, many organs have already been successfully modelled, including the lungs12–14, heart15–17, liver18,19, kidneys20, and skin21–23.
To model neutrophil transmigration during inflammation, the key components are the endothelial barrier and the ECM encountered post-transmigration. Neutrophils most commonly extravasate through post-capillary venules, which increase in permeability during inflammation. To recapitulate this, inflammatory mediators such as TNF-α are used to stimulate the endothelial barrier and induce production of inflammatory molecules that promote transmigration. After crossing the endothelium, neutrophils then encounter the basement membrane, a meshwork of proteins consisting primarily of collagen type IV, laminin, heparan sulfate proteoglycans, and nidogen24,25. Surrounding this, but further from the endothelial cells, is a fibrillar matrix containing collagen type I26. Neutrophil-ECM interactions occur directly through binding of neutrophil integrins to ECM proteins27,28 and indirectly via release of factors such as neutrophil proteases that remodel the ECM structure29. These interactions support neutrophil chemotaxis30–32 and prevent apoptosis33,34. Thus, the ECM is not simply a passive 3D scaffold but an active source of signals which sustains the inflammatory response35. Physiological ECM composition in organ-on-a-chip models is therefore important to understand how neutrophils navigate these matrices to reach the inflammatory site.
Although some organ-on-a-chip models have incorporated an endothelial component, this is usually a 2D sheet of endothelial cells on a porous membrane12,21 rather than a 3D vessel against a 3D ECM. A few groups have produced 3D neutrophil transmigration models36–39, investigating the role of chemoattractants, ECM pH, and endothelial cell type, but to our knowledge none have yet investigated the effect of ECM composition on endothelial and neutrophil responses to inflammation or inhibitors.
Here, we developed a novel model of neutrophil transmigration during inflammation, using the OrganoPlate system (Mimetas), a commercially available platform which has been used to model many organs already including the blood–brain barrier40,41, liver42,43, kidney44,45, and gut46–48, as well as the microvasculature49–51. The OrganoPlate consists of either 40 or 96 chips in a 384-well plate format, allowing the screening of many conditions in a more robust, reproducible, and high-throughput way than in-house manufacturing of individual devices. The OrganoPlate has been used to investigate the infiltration of neutrophils through a collagen I gel52 towards an inflamed intestinal tube, however this model did not include an endothelial component. It has also been used to study monocyte adhesion to the endothelium51, but no transmigration was observed in this model. Neither model considered the effect of the ECM on cell phenotype.
In this study, we used this platform to explore the effects of different ECM composition on trans endothelial neutrophil migration. This work demonstrates the importance of considering choice of ECM when designing organ-on-a-chip models. The multi-well plate format of the Organoplate enabled testing of anti-inflammatory compounds, supporting a use for the model in screening potential drug candidates for diseases involving excessive neutrophil infiltration and inflammation.
Results
HUVEC form confluent vessels in OrganoPlates on geltrex with 25% collagen I
The neutrophil transmigration model was constructed in a Mimetas OrganoPlate 3-lane. The 3-lane OrganoPlate consists of a 384-well plate containing 40 chips, each with three channels. The channels are separated by Phaseguides, a liquid pinning technology which enables vessels to be grown against ECM, without any physical separation by membranes53,54 (Fig. 1a).
Two different ECMs, geltrex and collagen I, were compared in the OrganoPlate. Geltrex consists of a mix of proteins found physiologically in the endothelial basement membrane. However, when HUVEC were grown against geltrex alone, cells differentiated into tubes on the ECM, preventing proper vessel formation (Fig. 1b.i, Supplementary Movie 1). In contrast, when collagen I was used HUVEC grew on all four sides of the channel, forming confluent vessels (Fig. 1b.ii, Supplementary Movie 2), as previously reported49,55–58. To produce a more physiologically relevant basement membrane without stimulating differentiation, a mixture of 75% geltrex and 25% collagen I was tested (referred to as geltrex mix from here). This prevented the tube formation seen with geltrex alone (Fig. 1b.iii, Supplementary Movie 3). Successful vessel formation was confirmed by staining of intercellular junctions and ability of vessels to retain 70 kDa dextrans (Fig. 1c).
TNF-α induces endothelial inflammation
To develop an inflammation model, vessels were grown in the top channel with ECM patterned into the middle channel. Stimulation of confluent vessels with TNF-α upregulated expression of ICAM-1 on the vessel surface (Fig. 2a). Analysis of cytokine release into supernatants from stimulated vessels showed upregulation of several inflammatory cytokines: soluble intercellular adhesion molecule-1 (ICAM-1), interleukin-8 (IL-8), C–X–C Motif Chemokine Ligand 1 (CXCL1), and C–C Motif Chemokine Ligand 2 (CCL2) (Fig. 2b). In contrast, macrophage migration inhibitory factor (MIF) and serine protease inhibitor E1 (SERPIN E1) were present in both unstimulated and stimulated samples. These data show that an inflammatory state was successfully induced in the vessels. There was no significant difference in cytokine expression between collagen I and geltrex mix, in either unstimulated or TNF-α stimulated vessels (Supplementary Fig. S2).
Neutrophils transmigrate upon inflammatory stimulation
Addition of freshly isolated human neutrophils into the inflamed vessels led to neutrophil transmigration out of the vessels and into the ECM (Fig. 3a.i). The use of human neutrophils increases the translational potential of this model, compared to use of immortalised cell lines. fMLP was added to the bottom channel to produce a gradient of chemoattractant for the neutrophils to migrate towards. Neutrophil transmigration was easily quantifiable by imaging due to the structure of the OrganoPlate, where the vessel and ECM are side by side. This allows straightforward analysis of both number of neutrophils transmigrated and the distance migrated within the ECM.
Very few neutrophils transmigrated across unstimulated vessels. Neutrophil transmigration differed between geltrex mix and collagen I ECMs. Fewer neutrophils transmigrated into collagen I, and post-transmigration neutrophils appeared unable to migrate towards the fMLP, stalling within 150 µm of the vessel. In contrast, neutrophils easily migrated throughout geltrex mix, covering the whole width of the gel channel during the 1.5-h experiment (Fig. 3a, Supplementary Fig. S3).
Interestingly, when the chemoattractant was not present, neutrophils still transmigrated into geltrex mix, although the number transmigrated was slightly reduced. In contrast, fMLP was required for transmigration into collagen I, with transmigration without fMLP comparable to unstimulated levels. The distance of migration in gel was not affected by presence of chemoattractant, in either geltrex mix or collagen I (Fig. 3b, Supplementary Fig. S3).
Pharmacological inhibition of neutrophil transmigration depends on vessel ECM
To investigate the potential of our model for testing anti-inflammatory or immunomodulatory compounds, we investigated the effect of inhibiting neutrophil proteases. A cocktail of protease inhibitors was used; an elastase inhibitor (sivelestat), a cathepsin G inhibitor (Cathepsin G Inhibitor 1), and a dual elastase and cathepsin G inhibitor (human recombinant SLPI). These were first tested in HUVEC-free OrganoPlates, to isolate their effect on neutrophil migration into the ECM. In this experiment, the ECM was plated 1 day before neutrophil addition. fMLP was added directly before neutrophil perfusion.
Neutrophils were unable to migrate into collagen I at all without HUVEC present (Fig. 4a). This suggests that the presence of HUVEC either makes the collagen I more permissible to migration, or that signalling between the HUVEC and neutrophils during transmigration activates the neutrophils and subsequently supports their migration. In contrast, neutrophils readily migrated into geltrex mix, when an fMLP gradient was present. This migration into geltrex mix was reduced by the protease inhibitor cocktail. The reduction seen was in numbers of neutrophils migrating rather than distance migrated in the ECM (Fig. 4b, Supplementary Fig. S4).
When HUVEC were incorporated into the model, number of neutrophils transmigrating into geltrex mix was inhibited by the protease inhibitor cocktail across (Fig. 4c). This inhibition was seen in all neutrophil donors tested. In contrast, this inhibition was not seen consistently in vessels grown against collagen I. Together, these data indicate that our inflammation-on-a-chip model can be used to explore the effect of potential immunomodulatory compounds Moreover, these results indicate that the effects of such immunomodulatory compounds can vary depending on the underlying ECM.
Discussion
In this study we present a new 3D in vitro model of neutrophil transendothelial migration and ECM infiltration. Confluent endothelial vessels were successfully cultured against two different types of ECM. The endothelial cells were stimulated to mimic an inflammatory state, leading to primary human neutrophil transmigration into the ECM. Significant differences were found between neutrophil transmigration into the different ECMs, including differences in response to pharmacological inhibition. This work highlights the ECM as an important modulator of cell phenotype, and ECM composition should therefore be considered carefully when designing complex in vitro models.
The Mimetas 3-lane OrganoPlate was chosen as the platform for the model, as it allows culture of cells under perfusion and against a 3D ECM without any physical separation by membranes or barriers53,54. This is important when studying direct cell-ECM interactions and cell migration across the vessel wall. The three-lane structure allows the endothelium to be accessed both apically and basally. Therefore, inflammatory stimuli can be added in a physiologically relevant manner. For example, in our model we established an fMLP gradient across the ECM to mimic signals from the site of inflammation. A caveat to the use of this system is that the flow present is bidirectional rather than the physiological unidirectional. Previous studies have found that endothelial cells do not elongate or align in the direction of flow when it is bidirectional59,60, and express higher levels of inflammatory cytokines than when under unidirectional flow60. However, the presence of bidirectional flow is favorable over static as it allows the rolling of neutrophils over the endothelium, a key step in the process of transmigration in vivo61. In addition, the convenience of a pump free system and the 384-well plate format allows higher throughput experiments and enables testing of many conditions simultaneously, making this system attractive for drug screening.
ECM composition is a major regulator of neutrophil infiltration and yet physiologically relevant ECM are often overlooked in favour of experimentally convenient substrates. Two types of ECM were tested in the model, collagen I and geltrex. Collagen I is well established as a 2D coating or 3D ECM for endothelial cells, as it robustly supports adherence and monolayer formation49,55–58. In contrast, studies on culturing endothelial cells on basement membrane extracts (BMEs) such as geltrex or matrigel focus on induction of tube formation, modelling angiogenesis62–64. Our initial findings mirror these approaches, with successful vessel formation on collagen I, and vessel retraction and tube formation against geltrex. However, by combining geltrex with a small amount of collagen I we were able to create an ECM composition that supported vessel formation. Physiologically, the ECM consists of a thinner layer of basement membrane similar to geltrex, with a thicker layer of interstitial collagen I matrix below. Although our in vitro model does not recapitulate this this bilayer, we are able to successfully culture vessels on a mixed matrix, exposing endothelial cells to a wider range of ECM components.
The difference in endothelial phenotype between collagen I and BMEs is probably due to multiple factors, including differences in stiffness of the gels and protein composition. A previous study cultured HUVEC on polyacrylamide gels, and found that as stiffness of the gel decreased HUVEC tended to undergo tube formation, but maintained monolayer formation at a higher stiffness65. Other studies have found the basement membrane protein laminin to play an important role in determining monolayer vs tube formation66–68. The basement membrane therefore influences endothelial phenotype, and so 3D models on ECM components have an opportunity to better represent the physiological microenvironment than 2D cultures, or 3D models on a single type of matrix protein.
Inflammation was induced in the vessels using TNF-α, a commonly used inflammatory stimulus, although other inflammatory stimuli could be readily compared in future studies. Immunofluorescence staining of surface ICAM-1, a key receptor for neutrophil binding, showed a significant upregulation upon stimulation. Analysis of vessel supernatants found induction of four inflammatory cytokines—soluble ICAM-1, CXCL1, CCL2 and IL-8. These cytokines have established roles in neutrophil transmigration69–72 and inflammatory diseases73–76 in vivo. Therefore, TNF-α was an appropriate stimulus for our model.
When neutrophils were added to stimulated vessels, differences in transmigration were observed depending on the ECM used. The first major difference seen was that many more neutrophils transmigrated into geltrex mix than collagen I, suggesting that vessels are more permissive to transmigration on geltrex mix. There is very little data directly comparing transmigration across endothelium on substrates of different protein composition, likely due to the propensity of HUVEC to undergo tube formation when cultured on BMEs. Studies have found that increasing stiffness of the ECM increases neutrophil transmigration77,78, and that this corresponds to changes in stability of cell–cell junctions, alongside increased upregulation of inflammatory markers and vascular permeability79–81. However, we found no difference in surface ICAM-1 or cytokine induction between the ECMs. It is possible that the differences we observe between the ECMs are due to the different protein compositions of geltrex mix and collagen I. Geltrex mix contains many different ECM components and growth factors that could alter HUVEC phenotype independently of mechanotransduction, demonstrating the importance of ECM composition in modelling inflammation.
Following transmigration, ability of neutrophils to infiltrate the ECM was hindered in collagen I compared to geltrex mix. This could again be due to mechanical differences between the ECMs, such as stiffness or pore size. Several groups have compared the structure of polymerized collagen I to BME gels, finding that although BME gels have smaller pores they are more deformable than collagen I matrices82,83. Furthermore, it could be that geltrex mix contains more binding sites for the neutrophils and therefore supports their migration. Previous studies have found that binding of neutrophils to ECM proteins such as laminin and mindin promotes their chemotaxis towards the inflammatory site84,85.
We also explored the requirement for a chemoattractant gradient in the model. Absence of fMLP in chips with geltrex mix did not significantly affect numbers or distance of neutrophils transmigrated. In contrast, vessels grown against collagen I required the presence of fMLP for induction of neutrophil transmigration. Geltrex mix itself does not induce neutrophil infiltration, as no neutrophil migration was observed into geltrex mix without HUVEC or fMLP present. Therefore, the threshold for induction of transmigration differs between the ECMs, with transmigration into collagen I requiring an extra inflammatory signal to direct the neutrophils across the endothelium.
We next investigated a role for neutrophil proteases in navigating the ECM post-transmigration. Whereas some reports suggest that neutrophils move passively through the basement membrane, favouring ‘low expression regions’ with lower protein concentration86–88, other studies support a role for neutrophils in releasing proteases to actively degrade the BM31,89–91. We first observed that neutrophils were unable to penetrate a collagen I matrix without HUVEC present, which suggests a role for the endothelium in supporting migration into the ECM. This could be due to activation or priming of the neutrophils during transmigration. Previous studies have found that post-transmigration neutrophils have an altered phenotype, including increased motility92, increased CD11b/CD18 expression92,93, and an increased ability to migrate through pericyte layers94. Alternatively, it could be that the HUVEC alter the underlying ECM, either by remodelling or by depositing their own ECM during culture. The ability of endothelial cells to degrade the ECM during angiogenesis is well established95–97, but whether remodelling of the ECM occurs in mature vessels is more uncertain.
In contrast to collagen I, neutrophils easily migrated into geltrex mix without presence of a vessel. Moreover, inhibiting elastase and cathepsin G moderately reduced this infiltration, demonstrating a contribution from neutrophil proteases. When the inhibitors were tested with vessels present, a modest but consistent inhibition of migration was seen in geltrex mix vessels. This was not seen in vessels formed on collagen I. This suggests that elastase and cathepsin G are partially responsible for enabling migration in geltrex mix. Other proteases such as matrix metalloproteinases (MMPs) have also been found to play a role in neutrophil infiltration, and may also play a role here98–100. The lack of effect in collagen I could indicate that these proteases are not involved in collagen I degradation, although there is evidence that in cell-free systems that both enzymes are able to perform this function101,102.
Our results emphasise the role of the ECM in modulating cell phenotype and response to inhibitors. Previous studies, particularly in the field of cancer, have also found that 3D environment and ECM composition affect drug efficacy. For example, several groups have found cancer cells to be less responsive to chemotherapy in 3D cultures than in 2D monolayers103,104, with one finding that fibronectin as a substrate increased the lack of responsiveness compared to collagen I103, and another showing increased resistance to chemotherapy in biological matrices compared to synthetic matrices104. These studies highlight that the ECM is a source of both mechanical and biological signals. Therefore, typical 2D cell cultures cannot accurately be used to test responses to drugs. Complex 3D models which recapitulate the in vivo microenvironment are needed for drug discovery. For example, inflammatory sites are often characterised by increased matrix stiffness105, which has been found to increase inflammation106 and reduce drug efficacy107. Future models could tailor ECM composition to each organ, disease, or person. Creation of bespoke ECM compositions will enable development of accurate models to increase understanding of cell behaviour in disease, and support drug development.
Conclusions
3D in vitro organ on a chip models have the potential to bridge the gap between current in vitro and in vivo models. Development of these models requires knowledge of the microenvironment being modelled, including the physical 3D structure and the cell types and signals present. Inflammatory diseases are often characterised by excessive neutrophil infiltration and associated ECM remodelling. Here, we have successfully established a neutrophil transmigration on a chip model where neutrophils transmigrate out of an endothelial vessel and through a 3D ECM environment, as they would in vivo. We found substantial differences in characteristics of neutrophil transmigration depending on the ECM used, including different responses to inhibitors. This work highlights how extracellular components influence cell behaviour, and demonstrates a need for accurate recapitulation of in vivo microenvironments when designing in vitro models. Further work is required to fine-tune ECM structures for use in models and to delineate exactly how the ECM alters cell phenotype.
Materials and methods
All materials were obtained from Sigma (UK) unless specified otherwise.
All experiments involving human participants was reviewed by the Human Biology Research Ethics Committee, University of Cambridge, with fully-informed, written consent in accordance with the Declaration of Helsinki.
HUVEC culture
Human umbilical vein endothelial cells (HUVEC, PromoCell, Germany) were cultured in Endothelial Growth Medium (Media, PromoCell) with 30 µg/mL gentamicin, in T25 or T75 tissue culture flasks. Cells were grown to confluence (37 °C, 5% CO2) and then passaged using PromoCell Detach Kit. HUVEC were used at passage 4.
Extracellular matrix (ECM) compositions
For collagen I ECM, 5 mg/mL rat tail collagen type I (ibidi, Germany) was neutralised by mixing at a ratio of 8:1:1 with 1 M HEPES and 37 g/L NaHCO3 producing a 4 mg/mL solution. For geltrex mix ECM, Geltrex™ LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Gibco, A1413302) was diluted to 14.6 mg/mL in media and then mixed at a ratio of 75:25 (v/v) with 3 mg/mL collagen I. 3 mg/mL collagen I was made by neutralisation of 5 mg/mL collagen I with 1 M NaOH and 7.5% (w/v) NaHCO3 as per the manufacturer’s protocol. For each batch of geltrex, preliminary screening experiments were performed to confirm successful vessel formation. Some batches of geltrex required additional coating of the ECM with 10 µg/mL fibronectin for 2 days to support HUVEC adhesion.
OrganoPlate® culture
Three-lane OrganoPlates® (Mimetas, 4003-400B, Netherlands) were used. 50 µL Hanks’ Balanced Salt Solution (without calcium and magnesium, HBSS, Gibco) was added to the observation windows to prevent chips from drying out. 1.75 µL geltrex mix or 1.85 µL collagen I was added to the middle lane of the chip via the gel inlet (Fig. 1a). ECMs were polymerised for 10 min (37 °C, 5% CO2), then 50 µL HBSS was added to the gel inlet to prevent ECM dehydration. Chips were incubated for a further 50 min, after which HBSS was aspirated from the gel inlets.
HUVEC were seeded into the top channel by addition of 2 µL cell suspension at 2 × 107/mL. Media was added to the top channel inlet and the plate incubated for 2 h on its side at a 70° angle (37 °C, 5% CO2) to allow cells to attach to the ECM. Media was then added to the top channel outlet and perfusion begun (8 min intervals, 7° angle) on the Mimetas OrganoFlow S plate rocker. Plates were incubated under perfusion for 7 days to enable optimal barrier function of the vessels. Media was refreshed every 2–3 days.
Barrier Integrity Assay
After 7 days of incubation, the barrier function of the vessels was tested. 0.5 mg/mL 70 kDa tetramethylrhodamine (TRITC)-dextran was added to the top channel for 30 min. Dye retention was imaged on a Leica SP5 confocal microscope. Barrier function was quantified by measuring the fluorescence in each channel in FIJI108 and then calculating the ratio of fluorescence in the vessel channel versus fluorescence in the ECM channel.
Neutrophil isolation
Blood was taken from volunteers by venepuncture into 3.8% (v/v) sodium citrate-containing vacutainers (Greiner Bio-One). The volunteers were healthy and free of medication for at least 10 days prior to venepuncture. Fully-informed, written consent was obtained in accordance with the Declaration of Helsinki, and use of blood was reviewed by the Human Biology Research Ethics Committee, University of Cambridge. Nine mL blood was layered onto 5 mL histopaque-1077 and then centrifuged (428g, 30 min, room temperature, no brake). All layers above the red blood cell pellet were aspirated and the pellet diluted 1:1 (v/v) with HBSS, and then further diluted 1:1 (v/v) with 2% (w/v) dextran. The resulting solution was left at room temperature for 45 min to allow red blood cells to sediment. The opaque top layer was removed and diluted 1:1 (v/v) with HBSS and then centrifuged (200g, 10 min, room temperature, medium braking/acceleration). The pellet was resuspended in 1 mL sterile, deionized water for 45 s to lyse residual red blood cells, then topped up to 15 mL with HBSS and centrifuged again (200g, 10 min, room temperature, medium braking/acceleration). The resulting neutrophil pellet was resuspended at 3.75 × 106/mL in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% (v/v) foetal calf serum.
Neutrophil transmigration in OrganoPlates®
On day 7 of culture, vessel lumens were stimulated with 1.6 ng/mL human recombinant tumour necrosis factor-alpha (TNF-α) (R&D Systems) overnight. Immediately before neutrophil perfusion, the bottom channels of the chips were filled with 200 nM N-formyl-methionyl-leucyl-phenylalanine (fMLP). Neutrophils were then added to the vessels for 1.5 h on the rocker (37 °C, 5% CO2). The number of independent neutrophil donors used are specified in the figure legends.
Protease inhibitor treatments
A cocktail of 100 µM sivelestat (Biotechne), 10 µM Cathepsin G Inhibitor 1 (Cambridge Bioscience), and 250 nM human recombinant secretory leukocyte peptidase inhibitor (SLPI) (Biotechne) was used. Neutrophils were incubated with the inhibitors or 0.2% (v/v) DMSO vehicle control for 15 min at room temperature before addition to the OrganoPlate®.
Immunofluorescence
Vessels were fixed with 4% (w/v) paraformaldehyde (Santa Cruz Biotechnology) for 15 min, washed twice for five minutes with PBS and then blocked with 2% (w/v) BSA for 30 min. Anti-CD31 antibody (Abcam, ab9498) in 2% (w/v) BSA was added and incubated overnight at room temperature on a plate rocker. Vessels were washed twice with PBS and then anti-mouse-647 (ThermoFisher) secondary antibody, Hoechst-33342 (ThermoFisher), and phalloidin-FITC (ThermoFisher) were added and incubated for 1.5 h at room temperature in the dark, on a rocker. Two more PBS washes were performed. Images were obtained on a Leica SP5 confocal microscope, using a 20× objective. 3D reconstructions were created in FIJI109. Neutrophil transmigration was quantified in FIJI using the Cell Counter plug in. A neutrophil was considered transmigrated if it was to the right of the endothelial barrier, which was identified by CD31 staining (Supplementary Fig. S1). Neutrophils co-localised with CD31 staining were not considered transmigrated.
Cytokine arrays
R&D Systems Cytokine Proteome Profiler Arrays were used to investigate cytokine production. Supernatants were taken from five chips 24 h after TNF-α stimulation and pooled together. Cytokine arrays were carried out as per manufacturer’s instructions, with the modified protocol for detection using AlexaFluor™ 790 Streptavidin (ThermoFisher). A LI-COR Odyssey Fc was used for detection of arrays. Cytokine levels were quantified by densitometry in FIJI. Cytokine expression was expressed as a % of the positive reference spots for each array.
Statistical analysis
Statistical analysis was performed in GraphPad Prism v9. All tests were carried out using matched analyses. Two-way ANOVA with Sidak’s multiple comparisons test was used to analyse differences in surface ICAM-1 levels, cytokine expression, or number of neutrophils transmigrated between collagen I and geltrex mix, and unstimulated versus TNF-α stimulated. One-way ANOVA with Tukey’s multiple comparisons test was used to compare differences in number of neutrophils transmigrated between unstimulated, TNF-α, and TNF-α + fMLP, and also to compare unstimulated, stimulated, and protease inhibitor-treated conditions. For differences in distance of neutrophil migration, paired two-tailed t tests were used. Values P < 0.05 were considered significant. In figure legends, N refers to independent experiments/neutrophil donors, and n refers to technical repeats (number of vessels) within donors.
Supplementary Information
Author contributions
R.R. designed, performed and analysed experiments and drafted the manuscript. K.J., K.H. supervised research direction and edited the manuscript. M.H. supervised research direction, designed experiments, and edited the manuscript.
Funding
This work was supported by an AstraZeneca-Cambridge PhD Studentship. Research in MTH lab is also supported by NC3Rs/BHF PhD studentship NC/N002350/1 and British Heart Foundation project Grant PG/20/12/34982.
Data availability
Data are available from the corresponding author on reasonable request.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-022-10849-x.
References
- 1.Filippi MD. Neutrophil transendothelial migration: Updates and new perspectives. Blood. 2019;133:2149–2158. doi: 10.1182/blood-2018-12-844605. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Margraf A, Ley K, Zarbock A. Neutrophil recruitment: From model systems to tissue-specific patterns. Trends Immunol. 2019;40:613–634. doi: 10.1016/j.it.2019.04.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Yamahashi, Y. et al. Integrin associated proteins differentially regulate neutrophil polarity and directed migration in 2D and 3D. Biomed. Microdevices. 17, 100 (2015). [DOI] [PMC free article] [PubMed]
- 4.Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J. Exp. Med. 1962;115:453–466. doi: 10.1084/jem.115.3.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Mestas J, Hughes CCW. Of mice and not men: Differences between mouse and human immunology. J. Immunol. 2004;172:2731–2738. doi: 10.4049/jimmunol.172.5.2731. [DOI] [PubMed] [Google Scholar]
- 6.Doeing DC, Borowicz JL, Crockett ET. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin. Pathol. 2003;3:3. doi: 10.1186/1472-6890-3-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Modi WS, Yoshimura T. Isolation of novel GRO genes and a phylogenetic analysis of the CXC chemokine subfamily in mammals. Mol. Biol. Evol. 1999;16:180–193. doi: 10.1093/oxfordjournals.molbev.a026101. [DOI] [PubMed] [Google Scholar]
- 8.Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide—Identification of problems and overcoming obstacles. Transl. Med. Commun. 2019;4:1–19. doi: 10.1186/s41231-019-0050-7. [DOI] [Google Scholar]
- 9.Low LA, Mummery C, Berridge BR, Austin CP, Tagle DA. Organs-on-chips: Into the next decade. Nat. Rev. Drug Discov. 2020 doi: 10.1038/s41573-020-0079-3. [DOI] [PubMed] [Google Scholar]
- 10.Wu Q, et al. Organ-on-a-chip: Recent breakthroughs and future prospects. Biomed. Eng. Online. 2020;19:1–19. doi: 10.1186/s12938-020-0752-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Liu, C., Oikonomopoulos, A., Sayed, N. & Wu, J. C. Modeling human diseases with induced pluripotent stem cells: From 2D to 3D and beyond. Dev.145, dev156166 (2018). [DOI] [PMC free article] [PubMed]
- 12.Huh D, et al. Reconstituting organ-level lung functions on a chip. Science (80-). 2010;328:1662–1668. doi: 10.1126/science.1188302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Benam KH, et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat. Methods. 2016;13:151–157. doi: 10.1038/nmeth.3697. [DOI] [PubMed] [Google Scholar]
- 14.Benam KH, et al. Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst. 2016;3:456–466.e4. doi: 10.1016/j.cels.2016.10.003. [DOI] [PubMed] [Google Scholar]
- 15.Marsano A, et al. Beating heart on a chip: A novel microfluidic platform to generate functional 3D cardiac microtissues. Lab Chip. 2016;16:599–610. doi: 10.1039/C5LC01356A. [DOI] [PubMed] [Google Scholar]
- 16.Liu H, et al. Heart-on-a-chip model with integrated extra- and intracellular bioelectronics for monitoring cardiac electrophysiology under acute hypoxia. Nano Lett. 2020;20:2585–2593. doi: 10.1021/acs.nanolett.0c00076. [DOI] [PubMed] [Google Scholar]
- 17.Abulaiti M, et al. Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function. Sci. Rep. 2020;10:19201. doi: 10.1038/s41598-020-76062-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Ho CT, et al. Liver-cell patterning Lab Chip: Mimicking the morphology of liver lobule tissue. Lab Chip. 2013;13:3578–3587. doi: 10.1039/c3lc50402f. [DOI] [PubMed] [Google Scholar]
- 19.Du Y, et al. Mimicking liver sinusoidal structures and functions using a 3D-configured microfluidic chip. Lab Chip. 2017;17:782–794. doi: 10.1039/C6LC01374K. [DOI] [PubMed] [Google Scholar]
- 20.Schutgens F, et al. Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nat. Biotechnol. 2019;37:303–313. doi: 10.1038/s41587-019-0048-8. [DOI] [PubMed] [Google Scholar]
- 21.Kwak BS, et al. Microfluidic skin chip with vasculature for recapitulating the immune response of the skin tissue. Biotechnol. Bioeng. 2020;117:1853–1863. doi: 10.1002/bit.27320. [DOI] [PubMed] [Google Scholar]
- 22.Wufuer M, et al. Skin-on-a-chip model simulating inflammation, edema and drug-based treatment. Sci. Rep. 2016;6:1–12. doi: 10.1038/srep37471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ramadan Q, Ting FCW. In vitro micro-physiological immune-competent model of the human skin. Lab Chip. 2016;16:1899–1908. doi: 10.1039/C6LC00229C. [DOI] [PubMed] [Google Scholar]
- 24.Jayadev R, Sherwood DR. Basement membranes. Curr. Biol. 2017;27:R207–R211. doi: 10.1016/j.cub.2017.02.006. [DOI] [PubMed] [Google Scholar]
- 25.Leclech, C., Natale, C. F. & Barakat, A. I. The basement membrane as a structured surface—Role in vascular health and disease. J. Cell Sci. 133, jcs239889 (2021). [DOI] [PubMed]
- 26.Witjas FMR, van den Berg BM, van den Berg CW, Engelse MA, Rabelink TJ. Concise review: The endothelial cell extracellular matrix regulates tissue homeostasis and repair. Stem Cells Transl. Med. 2019;8:375–382. doi: 10.1002/sctm.18-0155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Sheikh S, et al. Differing mechanisms of leukocyte recruitment and sensitivity to conditioning by shear stress for endothelial cells treated with tumour necrosis factor-alpha or interleukin-1beta. Br. J. Pharmacol. 2005;145:1052–1061. doi: 10.1038/sj.bjp.0706281. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Werr J, Xie X, Hedqvist P, Ruoslahti E, Lindbom L. β1 integrins are critically involved in neutrophil locomotion in extravascular tissue in vivo. J. Exp. Med. 1998;187:2091–2096. doi: 10.1084/jem.187.12.2091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Mezu-Ndubuisi OJ, Maheshwari A. The role of integrins in inflammation and angiogenesis. Pediatr. Res. 2021;89:1619–1626. doi: 10.1038/s41390-020-01177-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Steadman R, et al. Laminin cleavage by activated human neutrophils yields proteolytic fragments with selective migratory properties. J. Leukoc. Biol. 1993;53:354–365. doi: 10.1002/jlb.53.4.354. [DOI] [PubMed] [Google Scholar]
- 31.Mydel P, et al. Neutrophil elastase cleaves laminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils. J. Biol. Chem. 2008;283:9513–9522. doi: 10.1074/jbc.M706239200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Lin M, et al. Matrix metalloproteinase-8 facilitates neutrophil migration through the corneal stromal matrix by collagen degradation and production of the chemotactic peptide pro-gly-pro. Am. J. Pathol. 2008;173:144–153. doi: 10.2353/ajpath.2008.080081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kettritz R, et al. Extracellular matrix regulates apoptosis in human neutrophils. Kidney Int. 1999;55:562–571. doi: 10.1046/j.1523-1755.1999.00280.x. [DOI] [PubMed] [Google Scholar]
- 34.Ginis, I. & Faller, D. V. Protection from apoptosis in human neutrophils is determined by the surface of adhesion. Am. J. Physiol.272, C295-309 (1997). [DOI] [PubMed]
- 35.Korpos E, Wu C, Song J, Hallmann R, Sorokin L. Role of the extracellular matrix in lymphocyte migration. Cell Tissue Res. 2010;339:47–57. doi: 10.1007/s00441-009-0853-3. [DOI] [PubMed] [Google Scholar]
- 36.Ingram, P. N., Hind, L. E., Jiminez-Torres, J. A., Huttenlocher, A. & Beebe, D. J. An accessible organotypic microvessel model using iPSC-derived endothelium. Adv. Healthc. Mater.7, 10.1002/adhm.201700497 (2018). [DOI] [PMC free article] [PubMed]
- 37.McMinn PH, Hind LE, Huttenlocher A, Beebe DJ. Neutrophil trafficking on-a-chip: An in vitro, organotypic model for investigating neutrophil priming, extravasation, and migration with spatiotemporal control. Lab Chip. 2019;19:3697–3705. doi: 10.1039/C9LC00562E. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Han S, et al. A versatile assay for monitoring in vivo-like transendothelial migration of neutrophils. Lab Chip. 2012;12:3861–3865. doi: 10.1039/c2lc40445a. [DOI] [PubMed] [Google Scholar]
- 39.Chen MB, et al. On-chip human microvasculature assay for visualization and quantification of tumor cell extravasation dynamics. Nat. Protoc. 2017;12:865–880. doi: 10.1038/nprot.2017.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Wevers NR, et al. A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport. Fluids Barriers CNS. 2018;15:1–12. doi: 10.1186/s12987-018-0108-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Koo Y, Hawkins BT, Yun Y. Three-dimensional (3D) tetra-culture brain on chip platform for organophosphate toxicity screening. Sci. Rep. 2018;8:1–7. doi: 10.1038/s41598-018-20876-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Bircsak KM, et al. A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®. Toxicology. 2021;450:152667. doi: 10.1016/j.tox.2020.152667. [DOI] [PubMed] [Google Scholar]
- 43.Jang M, Kleber A, Ruckelshausen T, Betzholz R, Manz A. Differentiation of the human liver progenitor cell line (HepaRG) on a microfluidic-based biochip. J. Tissue Eng. Regen. Med. 2019;13:482–494. doi: 10.1002/term.2802. [DOI] [PubMed] [Google Scholar]
- 44.Petrosyan A, et al. A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier. Nat. Commun. 2019;10:1–17. doi: 10.1038/s41467-018-07882-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Vormann MK, et al. Nephrotoxicity and kidney transport assessment on 3D perfused proximal tubules. AAPS J. 2018;20:1–11. doi: 10.1208/s12248-018-0248-z. [DOI] [PubMed] [Google Scholar]
- 46.Naumovska E, et al. Direct on-chip differentiation of intestinal tubules from induced pluripotent stem cells. Int. J. Mol. Sci. 2020;21:1–15. doi: 10.3390/ijms21144964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Gijzen L, et al. An intestine-on-a-chip model of plug-and-play modularity to study inflammatory processes. SLAS Technol. 2020;25:585–597. doi: 10.1177/2472630320924999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Beaurivage C, et al. Development of a human primary gut-on-a-chip to model inflammatory processes. Sci. Rep. 2020;10:1–16. doi: 10.1038/s41598-020-78359-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Van Duinen V, et al. 96 perfusable blood vessels to study vascular permeability in vitro. Sci. Rep. 2017;7:1–11. doi: 10.1038/s41598-016-0028-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.van Duinen V, et al. Perfused 3D angiogenic sprouting in a high-throughput in vitro platform. Angiogenesis. 2019;22:157–165. doi: 10.1007/s10456-018-9647-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Poussin C, et al. 3D human microvessel-on-a-chip model for studying monocyte-to-endothelium adhesion under flow—Application in systems toxicology. Altex. 2020;37:47–63. doi: 10.14573/altex.1811301. [DOI] [PubMed] [Google Scholar]
- 52.Gjorevski N, et al. Neutrophilic infiltration in organ-on-a-chip model of tissue inflammation. Lab Chip. 2020;20:3365–3374. doi: 10.1039/D0LC00417K. [DOI] [PubMed] [Google Scholar]
- 53.Vulto P, et al. Phaseguides: A paradigm shift in microfluidic priming and emptying. Lab Chip. 2011;11:1596–1602. doi: 10.1039/c0lc00643b. [DOI] [PubMed] [Google Scholar]
- 54.Trietsch SJ, Israëls GD, Joore J, Hankemeier T, Vulto P. Microfluidic titer plate for stratified 3D cell culture. Lab Chip. 2013;13:3548–3554. doi: 10.1039/c3lc50210d. [DOI] [PubMed] [Google Scholar]
- 55.Yetkin-Arik B, et al. Endothelial tip cells in vitro are less glycolytic and have a more flexible response to metabolic stress than non-tip cells. Sci. Rep. 2019;9:1–17. doi: 10.1038/s41598-019-46503-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.van Duinen V, et al. Robust and scalable angiogenesis assay of perfused 3D human iPSC-derived endothelium for anti-angiogenic drug screening. Int. J. Mol. Sci. 2020;21:4804. doi: 10.3390/ijms21134804. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Junaid A, et al. Metabolic response of blood vessels to tnfα. Elife. 2020;9:1–28. doi: 10.7554/eLife.54754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Ragelle H, et al. Human retinal microvasculature-on-a-chip for drug discovery. Adv. Healthc. Mater. 2020;9:2001531. doi: 10.1002/adhm.202001531. [DOI] [PubMed] [Google Scholar]
- 59.Lee DW, Choi N, Sung JH. A microfluidic chip with gravity-induced unidirectional flow for perfusion cell culture. Biotechnol. Prog. 2019;35:e2701. doi: 10.1002/btpr.2701. [DOI] [PubMed] [Google Scholar]
- 60.Yang Y, et al. Pumpless microfluidic devices for generating healthy and diseased endothelia. Lab Chip. 2019;19:3212–3219. doi: 10.1039/C9LC00446G. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Maas SL, Soehnlein O, Viola JR. Organ-specific mechanisms of transendothelial neutrophil migration in the lung, liver, kidney, and aorta. Front. Immunol. 2018;9:2739. doi: 10.3389/fimmu.2018.02739. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Russo TA, Banuth AMM, Nader HB, Dreyfuss JL. Altered shear stress on endothelial cells leads to remodeling of extracellular matrix and induction of angiogenesis. PLoS ONE. 2020;15:e0241040. doi: 10.1371/journal.pone.0241040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Faulkner A, et al. A thin layer angiogenesis assay: A modified basement matrix assay for assessment of endothelial cell differentiation. BMC Cell Biol. 2014;15:41. doi: 10.1186/s12860-014-0041-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Lovecchio J, Pannella M, Giardino L, Calzà L, Giordano E. A dynamic culture platform enhances the efficiency of the 3D HUVEC-based tube formation assay. Biotechnol. Bioeng. 2020;117:789–797. doi: 10.1002/bit.27227. [DOI] [PubMed] [Google Scholar]
- 65.Deroanne CF, Lapiere CM, Nusgens BV. In vitro tubulogenesis of endothelial cells by relaxation of the coupling extracellular matrix-cytoskeleton. Cardiovasc. Res. 2001;49:647–658. doi: 10.1016/S0008-6363(00)00233-9. [DOI] [PubMed] [Google Scholar]
- 66.Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 1988;107:1589–1598. doi: 10.1083/jcb.107.4.1589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Stamati K, Priestley JV, Mudera V, Cheema U. Laminin promotes vascular network formation in 3D in vitro collagen scaffolds by regulating VEGF uptake. Exp. Cell Res. 2014;327:68–77. doi: 10.1016/j.yexcr.2014.05.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Shakado S, et al. Effects of extracellular matrices on tube formation of cultured rat hepatic sinusoidal endothelial cells. Hepatology. 1995;22:969–973. doi: 10.1002/hep.1840220339. [DOI] [PubMed] [Google Scholar]
- 69.Kunisada M, Hosaka C, Takemori C, Nakano E, Nishigori C. CXCL1 inhibition regulates UVB-induced skin inflammation and tumorigenesis in Xpa-deficient mice. J. Invest. Dermatol. 2017;137:1975–1983. doi: 10.1016/j.jid.2017.04.034. [DOI] [PubMed] [Google Scholar]
- 70.Reichel CA, et al. Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler. Thromb. Vasc. Biol. 2009;29:1787–1793. doi: 10.1161/ATVBAHA.109.193268. [DOI] [PubMed] [Google Scholar]
- 71.Williams AE, et al. Evidence for chemokine synergy during neutrophil migration in ARDS. Thorax. 2017;72:66–73. doi: 10.1136/thoraxjnl-2016-208597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Tajima A, Iwase T, Shinji H, Seki K, Mizunoe Y. Inhibition of endothelial interleukin-8 production and neutrophil transmigration by Staphylococcus aureus beta-hemolysin. Infect. Immun. 2009;77:327–334. doi: 10.1128/IAI.00748-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Hou SM, et al. CXCL1 contributes to IL-6 expression in osteoarthritis and rheumatoid arthritis synovial fibroblasts by CXCR2, c-Raf, MAPK, and AP-1 pathway. Arthritis Res. Ther. 2020;22:1–11. doi: 10.1186/s13075-020-02331-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Dewald O, et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res. 2005;96:881–889. doi: 10.1161/01.RES.0000163017.13772.3a. [DOI] [PubMed] [Google Scholar]
- 75.Cotton JA, et al. Interleukin-8 in gastrointestinal inflammation and malignancy: Induction and clinical consequences. Int. J. Interferon Cytokine Mediator Res. 2016;8:13–34. [Google Scholar]
- 76.Witkowska AM. Soluble ICAM-1: A marker of vascular inflammation and lifestyle. Cytokine. 2005;31:127–134. doi: 10.1016/j.cyto.2005.04.007. [DOI] [PubMed] [Google Scholar]
- 77.Onken MD, et al. Endothelial monolayers and transendothelial migration depend on mechanical properties of the substrate. Cytoskeleton. 2014;71:695–706. doi: 10.1002/cm.21203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Stroka KM, Aranda-Espinoza H. Endothelial cell substrate stiffness influences neutrophil transmigration via myosin light chain kinase-dependent cell contraction. Blood. 2011;118:1632–1640. doi: 10.1182/blood-2010-11-321125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Mambetsariev I, et al. Stiffness-activated gef-h1 expression exacerbates lpsinduced lung inflammation. PLoS ONE. 2014;9:e92670. doi: 10.1371/journal.pone.0092670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Meng F, et al. Attenuation of lipopolysaccharide-induced lung vascular stiffening by lipoxin reduces lung inflammation. Am. J. Respir. Cell Mol. Biol. 2015;52:152–161. doi: 10.1165/rcmb.2013-0468OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Huynh J, et al. Age-related intimal stiffening enhances endothelial permeability and leukocyte transmigration. Sci. Transl. Med. 2011;3:112–122. doi: 10.1126/scitranslmed.3002761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Anguiano M, et al. Characterization of three-dimensional cancer cell migration in mixed collagen-Matrigel scaffolds using microfluidics and image analysis. PLoS ONE. 2017;12:e0171417. doi: 10.1371/journal.pone.0171417. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Yadav SK, et al. Frontline science: Elevated nuclear lamin A is permissive for granulocyte transendothelial migration but not for motility through collagen I barriers. J. Leukoc. Biol. 2018;104:239–251. doi: 10.1002/JLB.3HI1217-488R. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Jia W, Li H, He YW. The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment. Blood. 2005;106:3854–3859. doi: 10.1182/blood-2005-04-1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Adair-Kirk TL, et al. A site on laminin α5, AQARSAASKVKVSMKF, induces inflammatory cell production of matrix metalloproteinase-9 and chemotaxis. J. Immunol. 2003;171:398–406. doi: 10.4049/jimmunol.171.1.398. [DOI] [PubMed] [Google Scholar]
- 86.Voisin MB, Pröbstl D, Nourshargh S. Venular basement membranes ubiquitously express matrix protein low-expression regions: Characterization in multiple tissues and remodeling during inflammation. Am. J. Pathol. 2010;176:482–495. doi: 10.2353/ajpath.2010.090510. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Poduval P, Sillat T, Virtanen I, Dabagh M, Konttinen YT. Immigration check for neutrophils in RA lining: Laminin α5 low expression regions act as exit points. Scand. J. Rheumatol. 2010;39:132–140. doi: 10.3109/03009740903198980. [DOI] [PubMed] [Google Scholar]
- 88.Wang S, et al. Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. J. Exp. Med. 2006;203:1519–1532. doi: 10.1084/jem.20051210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Chua F. Neutrophil elastase: Mediator of extracellular matrix destruction and accumulation. Proc. Am. Thorac. Soc. 2006;3:424–427. doi: 10.1513/pats.200603-078AW. [DOI] [PubMed] [Google Scholar]
- 90.Kryczka J, Boncela J. Proteases revisited: Roles and therapeutic implications in fibrosis. Mediators Inflamm. 2017;2017:1–14. doi: 10.1155/2017/2570154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Heck LW, Blackburn WD, Irwin MH, Abrahamson DR. Degradation of basement membrane laminin by human neutrophil elastase and cathepsin G. Am. J. Pathol. 1990;136:1267–1274. [PMC free article] [PubMed] [Google Scholar]
- 92.Gonzalez AL, El-Bjeirami W, West JL, McIntire LV, Smith CW. Transendothelial migration enhances integrin-dependent human neutrophil chemokinesis. J. Leukoc. Biol. 2007;81:686–695. doi: 10.1189/jlb.0906553. [DOI] [PubMed] [Google Scholar]
- 93.Paulsson JM, Jacobson SH, Lundahl J. Neutrophil activation during transmigration in vivo and in vitro A translational study using the skin chamber model. J. Immunol. Methods. 2010;361:82–88. doi: 10.1016/j.jim.2010.07.015. [DOI] [PubMed] [Google Scholar]
- 94.Ayres-Sander CE, et al. Transendothelial migration enables subsequent transmigration of neutrophils through underlying pericytes. PLoS ONE. 2013;8:e60025. doi: 10.1371/journal.pone.0060025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Liu J, et al. Synthetic extracellular matrices with tailored adhesiveness and degradability support lumen formation during angiogenic sprouting. Nat. Commun. 2021;12:1–12. doi: 10.1038/s41467-020-20314-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Vernon RB, Helene Sage E. Contraction of fibrillar type I collagen by endothelial cells: A study in vitro. J. Cell. Biochem. 1996;60:185–197. doi: 10.1002/(SICI)1097-4644(19960201)60:2<185::AID-JCB3>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
- 97.Davis GE, Senger DR. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005;97:1093–1107. doi: 10.1161/01.RES.0000191547.64391.e3. [DOI] [PubMed] [Google Scholar]
- 98.van Hinsbergh VWM, Engelse MA, Quax PHA. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 2006;26:716–728. doi: 10.1161/01.ATV.0000209518.58252.17. [DOI] [PubMed] [Google Scholar]
- 99.Veidal SS, et al. Assessment of proteolytic degradation of the basement membrane: A fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenes. Tissue Repair. 2011;4:22. doi: 10.1186/1755-1536-4-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Sand JM, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis - Validation of two novel biomarker assays. PLoS ONE. 2013;8:84934. doi: 10.1371/journal.pone.0084934. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Wang J, et al. Cathepsin G deficiency reduces periaortic calcium chloride injury-induced abdominal aortic aneurysms in mice. J. Vasc. Surg. 2015;62:1615–1624. doi: 10.1016/j.jvs.2014.06.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Kafienah W, Buhle DJ, Burnett D, Hollander AP. Cleavage of native type I collagen by human neutrophil elastase. Biochem. J. 1998;330:897–902. doi: 10.1042/bj3300897. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Håkanson M, Textor M, Charnley M. Engineered 3D environments to elucidate the effect of environmental parameters on drug response in cancer. Integr. Biol. 2011;3:31–38. doi: 10.1039/C0IB00074D. [DOI] [PubMed] [Google Scholar]
- 104.Edmondson R, Adcock AF, Yang L. Influence of matrices on 3D-cultured prostate cancer cells’ drug response and expression of drug-action associated proteins. PLoS ONE. 2016;11:e0158116. doi: 10.1371/journal.pone.0158116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Lampi MC, Reinhart-King CA. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Sci. Transl. Med. 2018;10:475. doi: 10.1126/scitranslmed.aao0475. [DOI] [PubMed] [Google Scholar]
- 106.Nakasaki, M. et al. The matrix protein Fibulin-5 is at the interface of tissue stiffness and inflammation in fibrosis. Nat. Commun.6, 8574 (2015). [DOI] [PMC free article] [PubMed]
- 107.Shen Y, et al. Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer. Cancer Cell. 2020;37:800–817.e7. doi: 10.1016/j.ccell.2020.05.005. [DOI] [PubMed] [Google Scholar]
- 108.Schindelin J, et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 2012;9:676–682. doi: 10.1038/nmeth.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Schmid B, Schindelin J, Cardona A, Longair M, Heisenberg M. A high-level 3D visualization API for Java and ImageJ. BMC Bioinform. 2010;11:274. doi: 10.1186/1471-2105-11-274. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data are available from the corresponding author on reasonable request.